Critical Path Institute Receives Regulatory Support for Liver Injury Biomarker Tucson, AZ — January 22, 2018 — Critical Path Institute (C-Path) announced today that the European Medicines Agency (E
miR-122 An Exploratory Biomarker of Liver Injury: An Industry Perspective on the State of the Science and Experiences Pre-Clinically and Clinically The Critical Path Institute’s Predictive Safety Testing Consortium (PSTC) hosted a webinar focused on providing an industry pers
March 2, 2017 Safety, Dosing, and Pharmaceutical Quality for Studies That Evaluate Medicinal Products (Including Biological Products) in Neonates Ward RM, Benjamin D, Barrett JS, Allegaert K, Portman R, Davis JM, Turner MA, and the International Neonatal Consortium. Safety, D
IMI SAFE-T and C-Path PSTC Obtain Regulatory Support for New Liver Safety Biomarkers Oct 17, 2016 IMI SAFE-T and C-Path PSTC Obtain Regulatory Support for New Liver Safety Biomarkers US FDA and EMA Let
Critical Path Institute Secures Regulatory Support For Skeletal Muscle Safety Biomarkers April 13, 2015 Critical Path Institute Secures Regulatory Support For Skeletal Muscle Safety Biomarkers FDA and EMA Letters of Sup
Nonclinical Safety Biomarkers of Drug-induced Vascular Injury: Current Status and Blueprint for the Future
